Antibody Information

General Information of This Antibody

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

mesoADC [Investigative]

ADC Info

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 88.80% (Day 18)	High GSDME expression (GSDME +++)
Method Description	Comparison of the maximum tested dose of mesoADC (4.4 mg/kg) to PBS vehicle or isotype control ADC confirmed the antitumor effectiveness of the ADC up to day 18 .
In Vivo Model	EMT6 CDX model
In Vitro Model	Mammary gland malignant neoplasms	EMT6 cells		CVCL_1923

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.25 ug/mL	High GSDME expression (GSDME +++)
Method Description	EMT6 cells were pulsed with 1 ug/mL mesoADC for 30min then chased for 30 and 60min at 37°C.
In Vitro Model	Mammary gland malignant neoplasms	EMT6 cells		CVCL_1923
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	9.50 ug/mL	Low GSDME expression (GSDME +)
Method Description	CT26 cells were pulsed with 1 ug/mL mesoADC for 30min then chased for 30 and 60min at 37°C.
In Vitro Model	Colon carcinoma	CT26 cells		CVCL_7254

References

Ref 1	An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer. J Immunother Cancer. 2023 Mar;11(3):e006274. doi: 10.1136/jitc-2022-006274.